PKS Advisory Services LLC Makes New $56,000 Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

PKS Advisory Services LLC acquired a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 10,500 shares of the company’s stock, valued at approximately $56,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Nwam LLC bought a new position in Corvus Pharmaceuticals in the third quarter valued at about $53,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at about $73,000. XTX Topco Ltd acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $74,000. Virtu Financial LLC bought a new stake in shares of Corvus Pharmaceuticals during the third quarter worth approximately $83,000. Finally, Three Bridge Wealth Advisors LLC acquired a new position in Corvus Pharmaceuticals in the fourth quarter valued at approximately $120,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRVS has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $15.00 price target (up from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.63.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS opened at $3.35 on Thursday. Corvus Pharmaceuticals, Inc. has a 52-week low of $1.30 and a 52-week high of $10.00. The stock has a market cap of $215.26 million, a P/E ratio of -3.60 and a beta of 0.91. The firm has a 50 day moving average price of $4.67 and a 200 day moving average price of $6.08.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06). Analysts predict that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.